{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:43:31Z","timestamp":1771389811465,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Tranexamic acid (TXA) is an anti-fibrinolytic agent that prevents degradation of fibrin by blocking the ability of plasminogen to bind to fibrin and the proteolytic activity of plasmin. TXA has been proven to be useful in reducing bleeding complications in multiple types of surgery. In this article, we will review the current usage of TXA in endoscopic surgeries for benign prostatic hyperplasia (BPH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The use of TXA for endoscopic BPH surgeries has mainly been studied for transurethral resection of the prostate (TURP). In the clinical trials assessing the use of TXA and TURP, TXA demonstrated reduced intraoperative bleeding independent of administration route. However, this did not consistently translate to reduced hospitalization or catheterization times. Evidence for the use of TXA and holmium laser enucleation of the prostate (HoLEP) has begun to emerge, and to date limited benefit has been demonstrated. This result is likely due to the excellent innate hemostatic control associated with the procedure. However, further studies are required to validate these findings. With recent innovation in new types of endoscopic BPH surgeries, the benefit of TXA during other types of BPH procedures also require more study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Within the context of endoscopic surgeries for BPH, TXA appears to have the most benefit when performing TURP. More evidence is required to conclude on the benefit in other types of BPH surgery including HoLEP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11934-025-01271-7","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:26:11Z","timestamp":1747452371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Utility of Tranexamic Acid in Endoscopic Surgeries for Benign Prostatic Hyperplasia"],"prefix":"10.1007","volume":"26","author":[{"given":"Nicolas","family":"Siron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelino","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Max","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"1271_CR1","unstructured":"Chauncey JM, Wieters JS. Tranexamic Acid. 2023, StatPearls."},{"key":"1271_CR2","unstructured":"Pfizer Injectables. Cyklokapron. U.S. Food and Drug Administration; 2021."},{"key":"1271_CR3","doi-asserted-by":"crossref","unstructured":"Wardrop D et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database Syst Rev, 2013(7): p. CD009733.","DOI":"10.1002\/14651858.CD009733.pub2"},{"issue":"10","key":"1271_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17100","volume":"17","author":"I Roberts","year":"2013","unstructured":"Roberts I, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of Tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1\u201379.","journal-title":"Health Technol Assess"},{"issue":"12","key":"1271_CR5","first-page":"e20473","volume":"13","author":"V Kovalev","year":"2021","unstructured":"Kovalev V, et al. Effectiveness of Tranexamic acid in reducing hemorrhage in isolated blunt solid organ injury. Cureus. 2021;13(12):e20473.","journal-title":"Cureus"},{"key":"1271_CR6","doi-asserted-by":"publisher","first-page":"e3054","DOI":"10.1136\/bmj.e3054","volume":"344","author":"K Ker","year":"2012","unstructured":"Ker K, et al. Effect of Tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.","journal-title":"BMJ"},{"issue":"12","key":"1271_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/bjs\/znac252","volume":"109","author":"UK Royal Colleges Tranexamic Acid in S","year":"2022","unstructured":"Royal Colleges Tranexamic Acid in Surgery Implementation Group UK, et al. Tranexamic acid for safer surgery: the time is now. Br J Surg. 2022;109(12):1182\u20133.","journal-title":"Br J Surg"},{"issue":"21","key":"1271_CR8","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMoa2201171","volume":"386","author":"PJ Devereaux","year":"2022","unstructured":"Devereaux PJ, et al. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022;386(21):1986\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"1271_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5489\/cuaj.8254","volume":"17","author":"J Kim","year":"2023","unstructured":"Kim J, et al. The impact of Tranexamic acid on perioperative outcomes in urological surgeries A systematic review and meta-analysis. Can Urol Assoc J. 2023;17(6):205\u201316.","journal-title":"Can Urol Assoc J"},{"key":"1271_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jclinane.2018.04.014","volume":"48","author":"MA Longo","year":"2018","unstructured":"Longo MA, Cavalheiro BT, de Oliveira GR, Filho. Systematic review and meta-analyses of Tranexamic acid use for bleeding reduction in prostate surgery. J Clin Anesth. 2018;48:32\u20138.","journal-title":"J Clin Anesth"},{"issue":"5","key":"1271_CR11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.urology.2004.07.008","volume":"64","author":"A Rannikko","year":"2004","unstructured":"Rannikko A, Petas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology. 2004;64(5):955\u20138.","journal-title":"Urology"},{"issue":"3","key":"1271_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5173\/ceju.2011.03.art13","volume":"64","author":"S Kumsar","year":"2011","unstructured":"Kumsar S, et al. Tranexamic acid decreases blood loss during transurethral resection of the prostate (TUR -P). Cent Eur J Urol. 2011;64(3):156\u20138.","journal-title":"Cent Eur J Urol"},{"issue":"16","key":"1271_CR13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/pros.24616","volume":"83","author":"W Vanderbruggen","year":"2023","unstructured":"Vanderbruggen W, et al. The effect of Tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double-blind, randomized controlled trial. Prostate. 2023;83(16):1584\u201390.","journal-title":"Prostate"},{"key":"1271_CR14","unstructured":"R., R., et al., Use of tranexemic acid as A topical agent to reduce bleeding during TURP: A novel technique! Int J Sci Res, 2018. 7(1)."},{"issue":"3","key":"1271_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/UA.UA_41_20","volume":"13","author":"A Gupta","year":"2021","unstructured":"Gupta A, et al. Efficacy of Tranexamic acid in decreasing primary hemorrhage in transurethral resection of the prostate: A novel combination of intravenous and topical approach. Urol Ann. 2021;13(3):238\u201342.","journal-title":"Urol Ann"},{"key":"1271_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.urology.2024.05.015","volume":"191","author":"T Diab","year":"2024","unstructured":"Diab T, et al. Intraprostatic injection of Tranexamic acid decrease blood loss during monopolar transurethral resection of the prostate: A randomized controlled clinical trial. Urology. 2024;191:119\u201326.","journal-title":"Urology"},{"issue":"1","key":"1271_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11\u20139.","journal-title":"J Urol"},{"issue":"2","key":"1271_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/end.2022.0407","volume":"37","author":"MA Assmus","year":"2023","unstructured":"Assmus MA, et al. Tranexamic acid does not improve outcomes of holmium laser enucleation of the prostate: A prospective randomized controlled trial. J Endourol. 2023;37(2):171\u20138.","journal-title":"J Endourol"},{"key":"1271_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.urology.2023.06.025","volume":"180","author":"YS Lee","year":"2023","unstructured":"Lee YS, et al. Tranexamic acid was not associated with a reduction in bleeding complications related to holmium laser enucleation of the prostate. Urology. 2023;180:209\u201313.","journal-title":"Urology"},{"issue":"6","key":"1271_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.euf.2022.04.013","volume":"8","author":"P Probst","year":"2022","unstructured":"Probst P, Desai M. Expectations facing reality: complication management after aquablation treatment for lower urinary tract symptoms. Eur Urol Focus. 2022;8(6):1733\u20135.","journal-title":"Eur Urol Focus"},{"key":"1271_CR21","doi-asserted-by":"crossref","unstructured":"Eid N, Hillelsohn J. (219) the impact of Tranexamic acid on hemoglobin levels and operating time in aquablation for benign prostatic hyperplasia: preliminary results from a retrospective Case\u2013Control study. J Sex Med, 2024. 21(Supplement_7).","DOI":"10.1093\/jsxmed\/qdae167.214"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01271-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-025-01271-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-025-01271-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:03:12Z","timestamp":1767985392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-025-01271-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1007\/s11934-025-01271-7","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"22 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"43"}}